Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARR
1901
Armour Residential REIT
ARR
$2.37B
| $4.62M | ﹤0.01% |
+51,744
| New | +$4.42M |
|
1902
Caesarstone
CSTE
$119M
| $4.62M | ﹤0.01% |
306,766
+33,006
| +12% | +$530K |
|
1903
Worthington Enterprises
WOR
$2.87B
| $4.61M | ﹤0.01% |
177,122
-132,680
| -43% | -$3.12M |
|
1904
Hawkins
HWKN
$2.74B
| $4.59M | ﹤0.01% |
200,400
+5,800
| +3% | +$123K |
|
1905
Amphenol
APH
$206B
| $4.59M | ﹤0.01% |
169,600
-140,400
| -45% | -$3.58M |
|
|
WIRE
1906
DELISTED
Encore Wire Corp
WIRE
| $4.59M | ﹤0.01% |
79,900
-26,137
| -25% | -$1.5M |
|
1907
Compañía de Cervecerías Unidas
CCU
$2.18B
| $4.58M | ﹤0.01% |
241,200
-100,700
| -29% | -$2M |
|
|
EB
1908
DELISTED
Eventbrite
EB
| $4.54M | ﹤0.01% |
225,100
+72,100
| +47% | +$1.38M |
|
1909
Transact Technologies
TACT
$53.2M
| $4.54M | ﹤0.01% |
413,600
+9,834
| +2% | +$113K |
|
|
ITI
1910
DELISTED
Iteris, Inc.
ITI
| $4.54M | ﹤0.01% |
909,200
+4,426
| +0.5% | +$22.5K |
|
1911
First Mid Bancshares
FMBH
$1.38B
| $4.53M | ﹤0.01% |
128,512
-3,200
| -2% | -$112K |
|
1912
VEON
VEON
$3.93B
| $4.52M | ﹤0.01% |
71,462
-44,896
| -39% | -$2.76M |
|
|
ARQL
1913
DELISTED
Arqule Inc
ARQL
| $4.51M | ﹤0.01% |
225,782
-435,291
| -66% | -$5.05M |
|
1914
Ovid Therapeutics
OVID
$528M
| $4.5M | ﹤0.01% |
1,084,709
+497,984
| +85% | +$1.57M |
|
1915
Zions Bancorporation
ZION
$10.5B
| $4.49M | ﹤0.01% |
86,395
-340,100
| -80% | -$16.5M |
|
1916
KT
KT
$9.11B
| $4.48M | ﹤0.01% |
+386,145
| New | +$4.4M |
|
1917
Fabrinet
FN
$20.4B
| $4.47M | ﹤0.01% |
69,000
+27,000
| +64% | +$1.56M |
|
1918
Vornado Realty Trust
VNO
$7.28B
| $4.47M | ﹤0.01% |
67,175
-105,124
| -61% | -$6.8M |
|
1919
Nicolet Bankshares
NIC
$3.75B
| $4.46M | ﹤0.01% |
60,395
-28,700
| -32% | -$2.02M |
|
1920
Global Indemnity Group
GBLI
$395M
| $4.45M | ﹤0.01% |
150,327
-4,437
| -3% | -$118K |
|
|
GSH
1921
DELISTED
Guangshen Railway Co. Ltd
GSH
| $4.45M | ﹤0.01% |
268,261
+4,600
| +2% | +$74.2K |
|
1922
Rocky Mountain Chocolate Factory
RMCF
$11.5M
| $4.44M | ﹤0.01% |
481,121
+5,020
| +1% | +$44.9K |
|
1923
Travelers Companies
TRV
$77.2B
| $4.43M | ﹤0.01% |
+32,372
| New | +$4.41M |
|
|
PETQ
1924
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $4.43M | ﹤0.01% |
176,800
-217,100
| -55% | -$5.39M |
|
1925
Alico
ALCO
$297M
| $4.42M | ﹤0.01% |
123,341
+37,917
| +44% | +$1.28M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.